Due to the global niche character of pharmaceutical biotechnology, research collaborations and market entries on an international level are essential. Agility and market knowledge are required to maintain an overview in a rapidly evolving environment and to initiate a sustainable internationalisation process.
Ikxinta, a life sciences advisory firm that originated in the Basque Country in 2018, collaborates with scientists, industry innovators, and investors to propel clients in scientific frontiers
Manufacturing of COVID vaccines showed that large-scale production of lipid nanoparticles (LNPs) as a delivery vehicle for mRNA vaccines is already possible. As nanocarrier-based formulations became mainstream, however, insufficiencies in existing technologies for routine GMP manufacturing became apparent. LEON is committed to bridging these technology gaps through its unique FR-JET technology and innovative manufacturing equipment.
Sino Biological, Inc., is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA, adjacent to the world-renowned Texas Medical Center.
For 25 years now, BioM has been the network organisation of the biotechnology sector in Munich and Bavaria. To shape the future of biotechnology, BioM identifies relevant and sustainable local, regional and global trends and creates a unique ecosystem for innovation and growth.
Individually customised therapies for every patient this is the vision of the future which numerous companies, research institutions, and clusters focusing on precision medicine in Saxony are working along the entire value creation chain. They are primarily active in oncology and have gained national and international acclaim and renown both in highly specialised cancer diagnostics and innovative treatment methods.
Austria has gained an outstanding reputation as a research location in the field of life sciences both as a vibrant hub for science and as a cluster for research-oriented and manufacturing companies. The ABA links international companies with this ecosystem
CAR-T therapies represent a new successful strategy for the treatment of hematological malignancies; however, recent studies have revealed some limitations, including the occurrence of graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndromes (CRS). This has prompted researchers to look for alternative, safer cells, such as natural killer (NK) cells 1. NK cells are lymphocytes that kill tumor cells and virus-infected cells non-specifically, without prior sensitization. CAR-NK therapy involves the modification of NK cells with mature chimeric antigen receptor (CAR) technology to exploit their unique target cell recognition mechanism and broad tumor-killing ability. Figure 1 illustrates the CAR-NK therapeutic strategy 1. Compared with CAR-T therapy, CAR-NK therapy has numerous advantages, such as lower GVHD and significantly reduced CRS toxicity and immune effector cell-associated neurotoxicity syndrome toxicity, which enhance overall safety 2, 3. In addition, NK cells have multiple tumor recognition sites, thus potentially reducing antigenic escape failure 4.
Life sciences is a priority sector for global economies. And Lithuania is emerging as an advanced innovation hub in Central and Eastern Europe. In the countrys well-established research and development scene, researchers and entrepreneurs are actively commercializing science to shape the future of healthcare and beyond.
The sector has grown elevenfold in the last ten years, making it one of the nations most valuable. Lithuania has top-level universities, cranking out 5-7 thousand STEM professionals early. And it is teeming with top labs and incubator spaces for biotech startups.
Life sciences is a priority sector for global economies. And Lithuania is emerging as an advanced innovation hub in Central and Eastern Europe. In the country’s well-established research and development scene, researchers and entrepreneurs are actively commercializing science to shape the future of healthcare and beyond.
The sector has grown elevenfold in the last ten years, making it one of the nation’s most valuable. Lithuania has top-level universities, cranking out 5-7 thousand STEM professionals early. And it is teeming with top labs and incubator spaces for biotech startups.